Broker recommendations for Banco Santander SA
The Banco Santander SA stock is rated at 1.826923 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Tuesday 11 August, 2020 by a total of 26 brokers. This means that the consensus of the 26 different brokers is leaning toward to moderate buy/hold.
4 (15.38%) Underweight
1 (3.85%) Hold
11 (42.31%) Overweight
2 (7.69%) Buy
Price target by analysts
The 24 latest analyst estimates, per Tuesday 11 August, 2020, show the following high, low and average price targets.
Target Average: 2.88 USD
Target High: 3.8 USD
Target Low: 2 USD
Nifty outlook and stock pick by HDFC Sec: Buy UltraTech Cement, Sanofi
Wednesday, 12 August 2020, 04:41:00
Read more about Nifty outlook and stock pick by HDFC Sec: Buy UltraTech Cement, Sanofi on Business Standard. NIfty has been forming higher tops and higher bottoms on the daily charts. Nifty is placed above 20,50,100 and 200 days moving averages, indicating bullish trend on all time frames
— Business Standard
Insulin Pens Market and COVID-19 Impact Assessment 2020-2030 Featuring Novo Nordisk, Eli Lilly & Co, Sanofi and Ypsomed – ResearchAndMarkets.com
Tuesday, 11 August 2020, 18:25:00
DUBLIN–(BUSINESS WIRE)–The “Insulin Pens (Diabetes Care Devices) – Global Market Analysis and Forecast Model (COVID-19 market impact)” report has been added to ResearchAndMarkets.com’s offering. The market model is built to visualize quantitative market trends within Diabetes Care Devices therapeutic area. This model discusses in detail the impact of COVID-19 on Insulin Pens market for the year 2020 and beyond. Each of the covered 39 country’s color-coded and fully-sourced market models are e
— Business Wire
80% return in 95 sessions! Analysts say this Dark Horse has miles to run
Tuesday, 11 August 2020, 10:37:24
The pharma sector emerged the dark horse in the ruins of the Covid-19 destruction on Dalal Street, and the BSE Healthcare index rallied some 80 per cent in 95 sessions to hit an all-time high of 19,720 on August 10 rising from its 52-week low of 10,948 hit on March 23.Increased demand for pharma goods amid the health emergency, better-than-expected June quarter earnings and the government’s push to reduce the country’s dependency on imports for active pharmaceutical ingredient (API) played their part in driving the rally.Some 117 stocks from the sector delivered an average return of 126 per cent during this period, with Bharat Immunological & Biologicals gaining the most at 490 per cent.It was followed by IOL Chemicals (up 410 per cent), Aarti Drugs (up 402 per cent), Marksans Pharma (up 364 per cent) and Venus Remedies (up 312 per cent). Other stocks on the list all delivered positive returns. “Prior to Covid, pharma was under-owned. It was a sector which did nothing for five years, and everyone was underweight on these stocks.
— Economic Times India
Bayer Names Lori Moore as Vice President, Head of U.S. Pharmaceutical Communications
Monday, 10 August 2020, 16:00:00
WHIPPANY, N.J.–(BUSINESS WIRE)–Lori Moore, former Managing Director at Deloitte, will be joining Bayer as Vice President, Head of Pharmaceutical Communications in the United States, the company announced today. Moore spent the last six years in senior communications roles at Deloitte, most recently as the Managing Director leading efforts to transform internal communications. Prior to joining Deloitte, Moore served in communications leadership positions at Novo Nordisk and Sanofi. In her new
— Business Wire
Friday, 7 August 2020, 17:30:03
Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.
— Yahoo Finance